title: Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.
abstract: Dasatinib has demonstrated durable clinical responses in patients, both as first-line and subsequent lines of therapy. Dasatinib use can result in pleural effusion in some patients, occurring any time during treatment and commonly characterized as mild to moderate in severity. Early identification of symptoms is essential in the proper management of pleural effusion. Prompt confirmation of diagnosis and management of pleural effusion can minimize morbidity and maximize the ability to preserve long-term clinical benefits with dasatinib. Here, we provide guidance on early identification and management of dasatinib-related pleural effusion.
authors.affiliation: Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: jcortes@mdanderson.org.
authors.forename: Jorge E
authors.initials: JE
authors.lastname: Cortes
authors.affiliation: Department of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Jimenez
authors.affiliation: Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Mauro
authors.affiliation: Pulmonary Service, Memorial Sloan Kettering Cancer Center, New York, NY.
authors.forename: Alex
authors.initials: A
authors.lastname: Geyer
authors.affiliation: Malignant Oncology Division, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
authors.forename: Javier
authors.initials: J
authors.lastname: Pinilla-Ibarz
authors.affiliation: Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.
authors.forename: B Douglas
authors.initials: BD
authors.lastname: Smith
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000069439:Dasatinib / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010996:Pleural Effusion / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D000069439:Dasatinib
keywords: Adverse events; Algorithms; BCR-ABL1; Fluid retention; Tyrosine kinase inhibitor